Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;22(6):1379.
doi: 10.3892/etm.2021.10815. Epub 2021 Sep 28.

Osteoporosis therapies and their mechanisms of action (Review)

Beomchang Kim  1 , Yong Jin Cho  2 , Wonbong Lim  1   2   3
Affiliations
Review

Osteoporosis therapies and their mechanisms of action (Review)

Beomchang Kim et al. Exp Ther Med. 2021 Dec.

Abstract

Osteoporosis is a common disease that affects millions of patients worldwide and is most common in menopausal women. The main characteristics of osteoporosis are low bone density and increased risk of fractures due to deterioration of the bone architecture. Osteoporosis is a chronic disease that is difficult to treat; thus, investigations into novel effective therapeutic methods are required. A number of studies have focused on determining the most effective treatment options for this disease. There are several treatment options for osteoporosis that differ depending on the characteristics of the disease, and these include both well-established and newly developed drugs. The present review focuses on the various drugs available for osteoporosis, the associated mechanisms of action and the methods of administration.

Keywords: bone formation; bone remodeling; bone resorption; fracture; menopause; osteoblast; osteoclast; osteoporosis treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Pharmacological action sites for osteoporosis. 1. Pre-osteoclast: Estrogen and SERMs. 2. Osteoclast: Calcitonin. 3. Bone resorption site: Cathepsin K inhibitor and bisphosphonates. 4. Osteoblast: Strontium ranelate, PTH and PTHrP analogues, and anti-sclerostin antibody. 5. Osteoclast and osteoblast: Denosumab. ER, estrogen receptor; SERM, selective estrogen receptor modulator; CT, calcitonin receptor; RANK, receptor activator of nuclear factor-κB; RANKL, receptor activator of nuclear factor-κB ligand; CaSR, calcium sensing receptor; LRP5/6, lipoprotein receptor-related protein 5 and 6; PTH, parathyroid hormone; PTHrP, PTH-related protein; OPG, osteoprotegerin.
Figure 2
Figure 2
Schematic diagram of mutant RANKL and inhibitory effect against RANKL during osteoclastogenesis. RANK, receptor activator of nuclear factor-κB; RANKL, receptor activator of nuclear factor-κB ligand; LGR4, leucine rich repeat containing G protein-coupled receptor 4; mt, mutant; wt, wild-type; NFATc1, nuclear factor of activated T-cells cytoplasmic 1.
See this image and copyright information in PMC

References

    1. Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D. Osteoporosis: A review of treatment options. P T. 2018;43:92–104. - PMC - PubMed
    1. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BE, Barrett-Connor E, Black D, Bonjour JP, et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporosis Int. 1999;10:259–264. doi: 10.1007/s001980050224. - DOI - PubMed
    1. Noh JY, Yang Y, Jung H. Molecular mechanisms and emerging therapeutics for osteoporosis. Int J Mol Sci. 2020;21(7623) doi: 10.3390/ijms21207623. - DOI - PMC - PubMed
    1. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520–2526. doi: 10.1002/jbmr.2269. - DOI - PMC - PubMed
    1. Langdahl BL. Overview of treatment approaches to osteoporosis. Br J Pharmacol. 2021;178:1891–1906. doi: 10.1111/bph.15024. - DOI - PubMed